Loading
TRIM24 (Transcription intermediary factor 1-alpha) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Prostate cancer, Lung cancer and 3 more.
Transcriptional coactivator that interacts with numerous nuclear receptors and coactivators and modulates the transcription of target genes. Interacts with chromatin depending on histone H3 modifications, having the highest affinity for histone H3 that is both unmodified at 'Lys-4' (H3K4me0) and acetylated at 'Lys-23' (H3K23ac). Has E3 protein-ubiquitin ligase activity.
Open Targets scores its association with cancer at 0.79 (direct and indirect evidence; datatypes affected pathway 0.96, literature 0.98, genetic association 0.44, somatic mutation 0.83, animal model 0.71). IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Prostate Adenocarcinoma.
In plain words · TRIM24 (Transcription intermediary factor 1-alpha) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Prostate cancer, Lung cancer and 3 more.
TRIM24 (Transcription intermediary factor 1-alpha) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Prostate cancer, Lung cancer and 3 more.
Transcriptional coactivator that interacts with numerous nuclear receptors and coactivators and modulates the transcription of target genes.
No product in this corpus aims at TRIM24 yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
First described 1997. Earliest sequence paper UniProt cites for the protein: Thenot et al, J. Biol. Chem, 1997, "Differential interaction of nuclear receptors with the putative human transcriptional coactivator hTIF1". Source.
Sources: HGNC HGNC:11812 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O15164 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000122779 (association with cancer (MONDO_0004992) 0.79; per-cancer scores at or above 0.5: ovarian cancer 0.51, non-Hodgkin lymphoma 0.51, breast cancer 0.53, lung cancer 0.53, leukaemia 0.60 (GraphQL API, CC0)); IntOGen TRIM24 (driver in 1 cohort (Act 1, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Transcriptional coactivator that interacts with numerous nuclear receptors and coactivators and modulates the transcription of target genes. Interacts with chromatin depending on histone H3 modifications, having the highest affinity for histone H3 that is both unmodified at 'Lys-4' (H3K4me0) and acetylated at 'Lys-23' (H3K23ac). Has E3 protein-ubiquitin ligase activity. During the DNA damage response, participates in an autoregulatory feedback loop with TP53. Early in response to DNA damage, ATM kinase phosphorylates TRIM24 leading to its ubiquitination and degradation. After sufficient DNA repair has occurred, TP53 activates TRIM24 transcription, ultimately leading to TRIM24-mediated TP53 ubiquitination and degradation. Location: Nucleus; Cytoplasm; Mitochondrion (UniProt). Locus 7q33-q34 (HGNC).
Query for this target: (TITLE:"TRIM24" OR ABSTRACT:"TRIM24" OR TITLE:"tripartite motif containing 24" OR ABSTRACT:"tripartite motif containing 24" OR TITLE:"Transcription intermediary factor 1-alpha" OR ABSTRACT:"Transcription intermediary factor 1-alpha" OR TITLE:"hTIF1" OR ABSTRACT:"hTIF1" OR TITLE:"Tif1a" OR ABSTRACT:"Tif1a" OR TITLE:"RNF82" OR ABSTRACT:"RNF82") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TRIM24, not a curated reading list.
Shares Leukaemia (all types), IntOGen, Breast cancer (all types), Non-Hodgkin lymphoma (all types).
Shares Leukaemia (all types), IntOGen, Lung cancer (all types), Breast cancer (all types).
Shares Leukaemia (all types), IntOGen, Lung cancer (all types), Breast cancer (all types).
Shares Leukaemia (all types), IntOGen, Lung cancer (all types), Breast cancer (all types).
Shares Leukaemia (all types), Ovarian cancer, Breast cancer (all types), Non-Hodgkin lymphoma (all types).
Shares Leukaemia (all types), IntOGen, Non-Hodgkin lymphoma (all types), Open Targets Platform.
Shares Leukaemia (all types), IntOGen, Breast cancer (all types), Non-Hodgkin lymphoma (all types).
Shares Leukaemia (all types), Ovarian cancer, Lung cancer (all types), Breast cancer (all types).